ArticleFrontiers in endocrinology2025
Objective perimetry and diabetic retinopathy progression: a 10-year follow-up study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We investigated 10-year retinal function changes in persons with type 2 diabetes (PWT2D) using the objectiveFIELD Analyser (OFA) to measure per-region sensitivity and response delay. We also examined which baseline measures predicted diabetic retinopathy (DR) progression. Methods: Participants underwent a comprehensive anterior and posterior segment examination at both visits. Participants were examined by four OFA test methods differing in visual field eccentricity and test duration, each producing per-region sensitivities and response delays. DR severity was graded using Early Treatment of Diabetic Retinopathy Study (ETDRS) scores. A generalized linear mixed-effects logistic regression model identified predictors of DR progression over 10 years. Results: At the 10-year follow-up, 16 PWT2D (11 men, mean age 67.3 ± 11.9 years) were reexamined and more than half (10 participants) exhibited DR progression by at least one ETDRS severity level. Average total deviations of the OFA30 test showed progressive sensitivity loss, particularly in peripheral and nasal regions, whereas response delays demonstrated radially symmetric defects for both OFA30 and OFA15. Logistic regression revealed that regional reduced sensitivity and prolonged delays were significantly associated with higher odds of DR progression, alongside clinical factors such as blood glucose, diabetes duration, biothesiometry score, and baseline DR severity. For OFA30, an initial sensitivity loss of 10 dB in the nasal field produced odds of progression of 1.74× (SE 1.50× and 2.03×, p<0.001). Initial central field delays of 10 ms increased odds by 1.12× (SE 1.08× and 1.15×, p<0.001). Linear models further confirmed that DR severity was significantly associated with changes in OFA sensitivity and response delay. Conclusion: The OFA may provide a rapid and convenient method for monitoring and predicting DR progression. By assessing changes in retinal function, OFA shows potential as a valuable tool for tracking disease progression and may offer greater sensitivity for detecting functional changes over time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.